NASDAQ$GPCR
Structure Therapeutics Inc · Q4 2024 earnings
Q4 2024 earnings · · Before market open · Investor relations
Briefing
Structure Therapeutics reported its financial results for the fourth quarter and full year ended December 31, 2024.
Structure Therapeutics reported a net loss of $36.479 million for the fourth quarter of 2024, compared to a net loss of $24.503 million in the same period last year. The company's cash, cash equivalents, and short-term investments totaled $883.518 million at year-end 2024, indicating a strong financial position.
- Aleniglipron (GSBR-1290) ACCESS and ACCESS II studies fully enrolled, with topline data anticipated by year-end 2025.
- Oral small molecule amylin receptor agonist (ACCG-2671) is undergoing IND-enabling activities, with Phase 1 initiation expected by year-end 2025.
- The company ended 2024 with a strong financial position, holding $883.5 million in cash, cash equivalents, and short-term investments.
- Research and Development expenses increased to $33.487 million in Q4 2024 from $20.042 million in Q4 2023, driven by increased headcount and advancement of the GLP-1R franchise.
Headline financials
Revenue & EPS history
Structure Therapeutics · Revenue · Quarterly
$0
Forward guidance
Structure Therapeutics anticipates 2025 to be a transformative year for its oral selective GLP-1 small molecules, with key clinical milestones expected for aleniglipron and ACCG-2671. The company expects its current cash to fund operations and clinical milestones through at least 2027.
Tailwinds
- 2025 is expected to be a transformative year for oral selective GLP-1 small molecules in obesity and related diseases.
- Aleniglipron is anticipated to have 36-week data by year-end 2025 and a potential best-in-class profile.
- ACCG-2671, an oral amylin receptor agonist, is expected to begin Phase 1 development by year-end 2025.
- The company's cash position is expected to fund projected operations and key clinical milestones through at least 2027.
- Robust pipeline of potential combination therapies currently being investigated.
Headwinds
- Results from earlier clinical studies may not be predictive of future results.
- Potential delays in the commencement, enrollment, and completion of planned clinical studies.
- Ability to obtain regulatory approval and commercialize therapeutic candidates is not guaranteed.
- Reliance on third parties, including clinical research organizations, manufacturers, suppliers, and collaborators, over which the company may not always have full control.
- Impact of global pandemics, inflation, tariffs, supply chain issues, rising interest rates, future bank failures, and other macroeconomic factors on the company's business.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 15 quarterly earnings reports · overlaid with Q4 2024
+1.2%
Avg return
Earnings day
-1.1%
Avg return
5 days after
+9.8%
Avg return
30 days after
40%
6 / 15 earnings
Positive
+14.8%
Q4 2024
Best reaction
-11.6%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -2.6% | -2.5% | -29.1% | |
| Q3 2025 | -2.0% | +7.3% | +3.3% | |
| Q1 2025 | -4.6% | -11.2% | -21.2% | |
| Q4 2024 | +14.8% | +13.1% | -0.6% | |
| Q3 2024 | +1.9% | -14.1% | -15.5% | |
| Q2 2024 | -0.8% | +0.9% | +8.6% | |
| Q1 2024 | -8.7% | -9.0% | +35.3% | |
| Q4 2023 | -2.5% | -5.9% | +15.1% | |
| Q3 2022 | +11.5% | +7.1% | +23.4% | |
| Q3 2023 | -11.6% | -1.6% | +7.2% | |
| Q2 2023 | -1.9% | -2.9% | -0.1% | |
| Q2 2022 | -1.9% | -2.9% | -0.1% | |
| Q1 2023 | +8.9% | +1.9% | +40.2% | |
| Q4 2022 | +8.9% | +1.9% | +40.2% | |
| Q1 2022 | +8.9% | +1.9% | +40.2% | |
| Q4 2021 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro